| 宋亦琪,任伟.慢性肾脏病肾性贫血的治疗进展[J].中国临床保健杂志,2020,23(6):738-742. |
| 慢性肾脏病肾性贫血的治疗进展 |
| Progress in the treatment of the anemia of chronic kidney disease |
| 投稿时间：2020-08-12 |
| DOI：10.3969/J.issn.1672-6790.2020.06.004 |
| 中文关键词: 肾疾病,慢性 贫血 药物疗法 综述 |
| 英文关键词: Kidney diseases,chronic Anemia Drug therapy Review 〖FL |
| 基金项目: |
|
| 摘要点击次数: 5268 |
| 全文下载次数: 5170 |
| 中文摘要: |
| 肾性贫血是慢性肾脏病患者的常见并发症。早期诊断及治疗,对于降低心血管事件发生率及全因死亡率有着重要的意义。肾性贫血的发生机制复杂,促红细胞生成素的不足、铁缺乏、缺氧诱导因子氧传感通路均参与其中。补充外源性促红细胞生成素及铁剂是肾性贫血治疗的核心,罗沙司他为肾性贫血提供了新的治疗手段。 |
| 英文摘要: |
| Renal anemia is a common complication in patients with chronic kidney disease.Early diagnosis and treatment play an important role in reducing cardiovascular events and mortality.The mechanism of renal anemia is complicated,lacking of erythropoietin,irondeficiency,and hypoxia-inducible factor oxygen sensing pathways are all involved.Exogenous supplementation of erythropoietin and iron is the core of the treatment of renal anemia.Roxastat,which has been marketed,provides a new treatment method for renal anemia. |
|
查看全文
|
| 关闭 |
|
|
|